

882-4462 (800.88.CIGNA)

If this is an URGENT request, please call (800)

Granix / Neupogen / Nivestym / Releuko

(filgrastim)

PHYSICIAN INFORMATION			PATIENT INFORMATION					
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*)					
Specialty:	* DEA, NPI or	TIN:	items on this form are completed.*					
Office Contact Person:			* Patient Name:					
Office Phone:		* Cigna ID: * Date of Birth:		Birth:				
Office Fax:	ffice Fax:		* Patient Street Address:					
Office Street Address:			City:	State:		Zip:		
City:	State:	Zip:	Patient Phone:	-				
Urgency:								
Medication requested: Granix Neup	ogen	☐ Nivestym	Releuko					
300 mcg/0.5 mL syringe 480 mcg/0.8 mL syringe 300 mcg/mL vial 480 mcg/1.6 mL vial Other (<i>please specify</i>): 480 mcg/1.6 mL vial								
Directions for use:	1	ICD10:						
Quantity:	!	Duration of therapy	erapy:		J-code:			
 Where will this medication be obtained? Accredo Specialty Pharmacy** Hospital Outpatient Prescriber's office stock (billing on a medical claim form) Other (please specify): 			 Retail pharmacy Home Healthcare **Cigna's nationally preferred specialty pharmacy 					
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557								
Facility and/or doctor dispens Facility Name: Address (City, State, Zip Code):	sing and adminis State:	tering medicatio	on: Tax ID#:					
Where will this drug be administered? Patient's Home Hospital Outpatient Physician's Office Other (please specify):								
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?								
Clinical Information: Which of the following is related to the use of this drug in this patient? Chemotherapy acute exposure to myelosuppressive radiation doses [hematopoietic syndrome of acute radiation syndrome (ARS)] hematopoietic cell transplant (HCT, HSCT) mobilization of autologous hematopoietic progenitor cells into peripheral blood for leukapheresis severe chronic neutropenia from congenital, cyclic, or idiopathic neutropenia other or unknown (<i>please specify</i>): (if chemotherapy) Which applies to your patient? chemotherapy for acute myeloid leukemia (AML) (induction or maintenance of remission) chemotherapy for any cancer that is NOT acute myeloid leukemia (non-myeloid) chemotherapy prior to bone marrow transplant (BMT)								

 (if non-myeloid) Is this a new start of therapy with Granix/Neupogen/Releuko OR is your patient starting a new cher Yes, new start/cycle No Unknown (if no) How many days of Granix/Neupogen/Releuko therapy are needed to complete this current cycle? Please doses already given for this cycle. 		-
Did your patient try and have documented failure/inadequate response or intolerance to any of the following? Chec Granix INeupogen INivestym IReleuko IZarxio For any drug checked, please provide date(s) taken and for how long, and what the documented results were of tak any intolerances your patient experienced.		-
(if no Granix) Is your patient able to use Granix? (if no) Please explain:	Yes 🗌	No 🗌
(if no Neupogen) Is your patient able to use Neupogen? (if no) Please explain:	Yes 🗌	No 🗌
(if no Nivestym) Is your patient able to use Nivestym? (if no) Please explain:	Yes 🗌	No 🗌
(if no Releuko) Is your patient able to use Releuko? (if no) Please explain:	Yes 🗌	No 🗌
(if no Zarxio) Is your patient able to use Zarxio? (if no) Please explain:	Yes 🗌	No 🗌
Is this a new start or continuation of therapy with the requested medication? If patient has been taking samples, ple ☐ New Start ☐ Continuation of therapy	ase pick "ne	ew start."
Is there documentation of a beneficial response to this medication?	Yes 🗌	No 🗌
Please provide support for continued use.		
Additional Information: (including labs and alternatives tried. Please include drug name, date(s) taken and for	how long, a	nd what the
documented results were of taking each drug, including any intolerances your patient experienced.)		
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that th its designees may perform a routine audit and request the medical information necessary to verify the accuracy of on this form.		
Prescriber Signature: Date:	<u> </u>	·
Save Time! Submit Online at: <u>www.covermymeds.com/main/prior-authorization-forms/cigna/</u> or via Sure	Scripts in y	our EHR.
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it us to expedite the request. View our Prescription Drug List and Coverage Policies online at cign		t that you call
		v010124

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005